ABBV vs INTC: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Intel Corp. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-15.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Intel Corp. · Technology
$107.76
-5.2% upside to fair value
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
INTC |
| Current Price |
$261.07 |
$107.76 |
| Fair Value Estimate |
$264.30 |
$102.16 |
| Upside to Fair Value |
+1.2%
|
-5.2%
|
| Market Cap |
$461.3B |
$541.6B |
| Forward P/E |
128.0x
|
-173.8x
|
| EV / EBITDA |
31.0x
|
49.9x
|
| Price / Sales |
7.3x
|
10.1x
|
| Price / FCF |
22.1x
|
-173.7x
|
| Revenue Growth YoY |
+12.4%
|
+7.2%
|
| Gross Margin |
70.7%
|
35.4%
|
| Operating Margin |
27.6%
|
-9.4%
|
| Return on Equity |
68.0%
|
-3.0%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
—
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Intel Corporation is a leading semiconductor company operating in the technology sector, specializing in designing and manufacturing microprocessors and related technologies. The business quality is currently low due to negative earnings growth of 354.1% in the most recent quarter and negative profitability metrics including a net margin of -5.9% and an operating margin of -9.4%. Despite a revenu…
Accumulation Zones
| Metric |
ABBV |
INTC |
| Zone Low |
$198.23 |
$76.62 |
| Zone High |
$224.66 |
$86.84 |
| In Buy Zone? |
No
|
No
|